P-263 The role of biologic targets in metastatic colorectal cancer in non-elderly patients: A single institutional analysis

Abstract

Conclusion:The naïve indirect treatment comparison to state-of-the-art therapy indicated that P-32 microparticles combined with standard-of-care chemotherapy may provide significant and clinically relevant benefits for patients with unresectable LAPC and a valuable treatment option in an area of high unmet medical need.Legal entity responsible for the study: OncoSil Medical Ltd.